Wanbury Ltd Share Price

Overview

Wanbury Ltd share price is currently ₹262.82, up by ₹4.22 (1.63%) from its previous closing price of ₹258.60. The share price has declined -18.62% over the past month and declined -1.84% over the past year. The stock's 52-week low and high are ₹158.12 and ₹355.03, respectively. Wanbury Ltd has a market capitalisation of ₹ 930.00 Cr. The share price was last updated on 25 Aug 2026, 03:52 PM IST.

Wanbury Ltd

WANBURY

₹0.00

₹4.22

1.63%

Healthcare

₹0.00(%)1D

Updated: 25 Aug 2026, 03:52:11 pm IST

Market Data

Open Price

₹261.33

Prev. Close

₹258.60

₹259.49

Day Low

₹268.53

Day High

₹158.12

52 Week Low

₹355.03

52 Week High

HealthcarePharmaceuticals & Drugs

CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

16.42

Sector PE

42.03

PB Ratio

16.75

Sector PB

5.82

EPS

16.01

Dividend Yield

0.00

Today's Volume

102.687 K

5 Day Avg. Volume

197.404 K

PEG Ratio

-0.36

Market Cap.

₹ 930.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
Motilal Oswal BSE Healthcare ETF	515	526 (2.14%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth	264	283 (7.2%)

About Wanbury Ltd 👋

Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.